Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Supports Class II Status For Oxygenation Circuit Devices, And Two Other Categories

This article was originally published in The Gray Sheet

Executive Summary

The Circulatory System Devices Panel supported class II, with special controls, reclassification proposals from FDA for extracorporeal membrane oxygenators; external cardiac compressors; and external pacemaker pulse generators and triple chamber pacing system analyzers. But the panel had some additional requests for further action by the agency.

Advertisement

Related Content

Oxygenation Circuit Devices Find A Class II Home With FDA
FDA Proposes Class II Status For External Pacemaker Pulse Generators, Analyzers
FDA Panel Supports Down-Classification For ECMO Circuits
Regulatory Briefs: Contact Lenses; Circ Panel; Wheelchair Reclassification
FDA Calling For More PMAs Than 510(k)s In Final Set Of Preamendment Devices
Class Act: Status Of CDRH’s 515 Initiative

Topics

Advertisement
UsernamePublicRestriction

Register

MT032428

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel